Bayer raises its brand profile

BayerThe Bayer Group plans to greatly strengthen the "Bayer" umbrella brand and steadily reduce the number of its other corporate brands. "We have thoroughly analyzed our brand portfolio and found that the diversity of brands in the Bayer Group has diluted the umbrella brand," explained Dr. Marijn Dekkers, Chairman of the Board of Management. "Our goal is to significantly increase the value of our brand portfolio by concentrating on the umbrella brand and our product brands. The Bayer cross enjoys world renown and has an excellent international reputation that we will continue to build on in the future."

The brand portfolio is to be clearly structured, raising Bayer's profile and further improving the perception and reputation of the company. The independent brand presences of individual units within the subgroups and service companies will be gradually discontinued. For example, the pharmaceuticals business will no longer be conducted under the name "Bayer Schering Pharma*" but only under the "Bayer HealthCare" brand. "We remain very strongly focused on our pharmaceutical activities in the future and therefore on Berlin. But we are sure that the global perception will benefit from our focus on the "Bayer" umbrella brand," said Dekkers.

The new branding strategy is also designed to accelerate and enhance the recognition of Bayer products. "The association of high-quality product brands with the brand icon "Bayer" creates trust and loyalty and thus improves the company's competitiveness," Dekkers commented.

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. The company's products and services are designed to benefit people and improve their quality of life. At the same time Bayer creates value through innovation, growth and high earning power. The Group is committed to the principles of sustainable development and to its role as a socially and ethically responsible corporate citizen. Economy, ecology and social responsibility are corporate policy objectives of equal rank. In fiscal 2009, Bayer employed 108,400 people and had sales of €31.2 billion. Capital expenditures amounted to €1.7 billion, R&D expenses to €2.7 billion.

* The name "Bayer Schering Pharma" as used in this news release refers to Bayer Schering Pharma AG, Berlin, Germany.

Most Popular Now

Pfizer announces positive top-line results from Ph…

Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the Phase 3 BENEGENE-2 study (NCT03861273) evaluating fidanacogene elaparvovec, an investigational ...

Time-restricted eating reshapes gene expression th…

Numerous studies have shown health benefits of time-restricted eating including increase in life span in laboratory studies, making practices like intermittent fasting a ...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

COVID-19 vaccines, prior infection reduce transmis…

Vaccination and boosting, especially when recent, helped to limit the spread of COVID-19 in California prisons during the first Omicron wave, according to an analysis by ...

Enzyme that protects against viruses could fuel ca…

An enzyme that defends human cells against viruses can help drive cancer evolution towards greater malignancy by causing myriad mutations in cancer cells, according to a ...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...